Lactiplantibacillus plantarum 299v
Also called: Lactobacillus plantarum 299v, L. plantarum 299v, L. plantarum DSM 9843, Lp299v
Lactiplantibacillus plantarum 299v (DSM 9843), formerly Lactobacillus plantarum 299v, is a probiotic bacterial strain isolated from healthy human intestinal mucosa by scientists at Lund University, Sweden. Its genome sequence is public. Results here are for 299v.
- Category
- Probiotic
- Forms
- Live bacteria, freeze-dried in capsules, tablets or powder sachets and used in foods; amounts stated in CFU
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2026 strain-specific meta-analysis pooled 6 randomized placebo-controlled trials of L. plantarum 299v (DSM 9843) given as a single strain in irritable bowel syndrome. [3]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BSeveral areas, whole body or blood2 topics
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Irritable bowel syndrome symptoms in adults (pooled single-strain trials) | B | A 2026 meta-analysis of 6 placebo-controlled RCTs of 299v alone found lower abdominal pain severity and more patients reporting symptom improvement, but no significant effect on bloating or constipation resolution; heterogeneity varied. [3] |
| Irritable bowel syndrome global symptoms (broad meta-analysis) | B | A 2023 meta-analysis of 82 IBS trials (10,332 patients) rated the certainty of evidence for a benefit of L. plantarum 299V on global symptoms as low. [4] |
| Irritable bowel syndrome (largest single trial) | B | In a double-blind RCT of 214 patients meeting Rome III criteria, 4 weeks of 299v lowered abdominal pain severity and frequency and bloating versus placebo. [6] |
| Iron absorption | B | A 2019 meta-analysis of 8 studies found higher iron absorption with Lp299v (standardized mean difference 0.55); among trials of iron status, only one Lp299v study showed improved serum iron. [5] |
| Outcomes of adults in intensive care | X | In a multicenter RCT of 218 adult ICU patients, 60 days of 299v did not change days alive and out of hospital (median 49.5 vs 49.0) or nosocomial infection (7.3% vs 4.6%). [7] |
Main constituents: L. plantarum 299v (formerly Lactobacillus plantarum 299v); genome sequence in GenBank (NZ_LEAV01000004) [2]; Genus Lactiplantibacillus: one of 23 novel genera proposed in the 2020 reclassification of Lactobacillus [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- IBS trial (214 patients): one capsule of 299v daily for 4 weeks. [6]
- ICU trial (218 patients): capsules containing 2 x 10^10 CFU of 299v, started at enrollment and continued for 60 days. [7]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines1 listed
Antibiotics (timing)
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada probiotics monograph (April 24, 2026), Table 1 bacteria including Lactiplantibacillus plantarum: 1.0 x 10^7 total CFU or more per day …
Details and sources
- In the 2026 IBS meta-analysis, adverse-effect rates with 299v did not differ significantly from placebo. [3]
- In the 218-patient ICU trial there were no serious or probiotic-associated adverse events. [7]
- A 2021 review states that 299v is safe for human consumption and does not confer antibiotic resistance. [2]
- FDA (2023, probiotics in general): administering probiotics to preterm infants may cause infection or invasive and potentially fatal disease; FDA reported one infant death and more than two dozen other adverse events. [8]
- Health Canada's probiotics monograph: do not use if you have an immune-compromised condition (for example AIDS, lymphoma or long-term corticosteroid treatment). [9]
Interactions
| With | What happens |
|---|---|
| Antibiotics (timing) | Health Canada's probiotics monograph directs taking the bacteria in its Table 1, which includes Lactiplantibacillus plantarum, at least 2–3 hours before or after antibiotics. [9] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- In freeze-dried form, 299v is described as robust and stable at room temperature, allowing long shelf lives for capsules, tablets and powder sachets. [2]
- Health Canada requires each strain to be identified by phenotype and genotype (including whole-genome strain characterization), absence of virulence to be shown, and at least 80% of the label-declared quantity to remain at the end of shelf life. [9]
- US labels must list total microorganism weight, which can include live and dead cells; CFU may be listed voluntarily. [8]
Regulatory status
- Canada: Lactiplantibacillus plantarum (formerly Lactobacillus plantarum) is listed in Health Canada's probiotics monograph (April 24, 2026) for general uses; labels must state the strain designation. [9]
- US: No NDI notification naming L. plantarum 299v was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30); other L. plantarum strains appear. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [10]
- US: FDA's GRAS Notice Inventory lists GRN 685 (L. plantarum strain 299v in conventional foods at up to 10^11 CFU per serving); FDA's letter (closed October 31, 2017): 'FDA has no questions'. [11]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [12]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Live Lactiplantibacillus plantarum 299v (formerly Lactobacillus plantarum 299v) Probiotic bacterium (family Lactobacillaceae) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming L. plantarum 299v was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30); other L. plantarum strains appear. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
- FDA's GRAS Notice Inventory lists GRN 685 (L. plantarum strain 299v in conventional foods at up to 10^11 CFU per serving); FDA's letter (closed October 31, 2017): 'FDA has no questions'. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of Lactiplantibacillus plantarum 299v was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-30). [P6]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Antibiotics (timing): Health Canada's probiotics monograph directs taking the bacteria in its Table 1, which includes Lactiplantibacillus plantarum, at least 2–3 hours before or after antibiotics. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P8]
- Strain identity by phenotype and genotype (genome-based comparison to type strains and whole-genome strain characterization) — Required by Health Canada's probiotics monograph for each live microorganism. [P5]
- Viable count (CFU) at end of shelf life — Health Canada requires at least 80% of the label-declared quantity at the end of shelf life. [P5]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- A 2021 review states that 299v survives the human gastrointestinal tract, adheres to mannose residues on intestinal epithelial cells and has in some cases been re-isolated more than ten days after intake stopped. [P4]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada probiotics monograph (April 24, 2026), Table 1 bacteria including Lactiplantibacillus plantarum: 1.0 x 10^7 total CFU or more per day (total from all live microorganisms in the product) for its general uses. [P5]
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Zheng J, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol 2020;70(4):2782-2858 (PMID 32293557), 2020-04. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory: GRN No. 685, Lactobacillus plantarum strain 299v (date of closure Oct 31, 2017), 2017-10-31. hfpappexternal.fda.gov
- Nordström EA, et al. Lactiplantibacillus plantarum 299v (LP299V): three decades of research. Benef Microbes 2021;12(5):441-465 (PMID 34365915), 2021-10-11. pubmed.ncbi.nlm.nih.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- Zheng J, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol 2020;70(4):2782-2858 (PMID 32293557), 2020-04. pubmed.ncbi.nlm.nih.gov
- Nordström EA, et al. Lactiplantibacillus plantarum 299v (LP299V): three decades of research. Benef Microbes 2021;12(5):441-465 (PMID 34365915), 2021-10-11. pubmed.ncbi.nlm.nih.gov
- Maslennikov R, et al. Strain-specific systematic review with meta-analysis of probiotics efficacy in the treatment of irritable bowel syndrome. J Clin Med 2026;15(3):1152 (PMID 41682832; full text PMC12898053), 2026-02-02. pmc.ncbi.nlm.nih.gov
- Goodoory VC, et al. Efficacy of probiotics in irritable bowel syndrome: systematic review and meta-analysis. Gastroenterology 2023;165(5):1206-1218 (PMID 37541528), 2023-11. pubmed.ncbi.nlm.nih.gov
- Vonderheid SC, et al. A systematic review and meta-analysis on the effects of probiotic species on iron absorption and iron status. Nutrients 2019;11(12):2938 (PMID 31816981), 2019-12-03. pubmed.ncbi.nlm.nih.gov
- Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012;18(30):4012-8 (PMID 22912552), 2012-08-14. pubmed.ncbi.nlm.nih.gov
- Litton E, et al. Early and sustained Lactobacillus plantarum probiotic therapy in critical illness: the randomised, placebo-controlled, restoration of gut microflora in critical illness trial (ROCIT). Intensive Care Med 2021;47(3):307-315 (PMID 33566129; full text PMC7873510), 2021-03. pmc.ncbi.nlm.nih.gov
- NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory: GRN No. 685, Lactobacillus plantarum strain 299v (date of closure Oct 31, 2017), 2017-10-31. hfpappexternal.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in probiotic: Akkermansia muciniphila (pasteurized) · Bacillus coagulans (Heyndrickxia coagulans) · Bifidobacterium animalis subsp. lactis BB-12 · Escherichia coli Nissle 1917 (EcN) · Lacticaseibacillus paracasei strain Shirota (LcS) · Lacticaseibacillus rhamnosus GG (LGG) · Limosilactobacillus reuteri DSM 17938 · Probiotics · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.